185 related articles for article (PubMed ID: 25031741)
1. Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population.
Liu X; Guan Y; Zhang W; Liu S; Liu J; Wang L; Niu Y
Int J Clin Exp Pathol; 2014; 7(6):3202-12. PubMed ID: 25031741
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
3. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
6. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
7. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.
Morrison DH; Rahardja D; King E; Peng Y; Sarode VR
Br J Cancer; 2012 Jul; 107(2):382-7. PubMed ID: 22713661
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study.
Nicolini A; Campani D; Miccoli P; Spinelli C; Carpi A; Menicagli M; Ferrari P; Gadducci G; Rossi G; Fini M; Giavaresi G; Bonazzi V; Giardino R
Int J Biol Markers; 2004; 19(4):275-81. PubMed ID: 15646833
[TBL] [Abstract][Full Text] [Related]
9. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
10. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma.
Zekioglu O; Erhan Y; Ciris M; Bayramoglu H; Ozdemir N
Histopathology; 2004 Jan; 44(1):18-23. PubMed ID: 14717664
[TBL] [Abstract][Full Text] [Related]
11. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study.
Castellano I; Marchiò C; Tomatis M; Ponti A; Casella D; Bianchi S; Vezzosi V; Arisio R; Pietribiasi F; Frigerio A; Mano MP; Ricardi U; Allia E; Accortanzo V; Durando A; Bussolati G; Tot T; Sapino A
Mod Pathol; 2010 Feb; 23(2):260-9. PubMed ID: 19915523
[TBL] [Abstract][Full Text] [Related]
14. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
Shokouh TZ; Ezatollah A; Barand P
Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
16. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
18. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract][Full Text] [Related]
19. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]